Breast NeoplasmsNCT07850323
Safety and Effectiveness of Robotic-Assisted Remote Surgery for Breast Tumors
An observational study of Breast Neoplasms, run by Guangzhou Women and Children's Medical Center at 1 site in China.
Trial summary
This is a multicenter retrospective clinical study. The research aims to explore the safety and efficacy of robotic single-port thoracoscopic minimally invasive surgery for breast cancer patients. Patients receiving robotic single-port thoracoscopic surgery for breast tumors will be enrolled. Read more about this study
- Who is it for?
- Ages 18 to 85 years, women only
- Conditions the study is for
- Breast Neoplasms
- What is being tested?
- Robotic-assisted axillary lymph node dissection
- Type of treatment
- Surgery or procedure
- How many people
- 25 participants
- Where
- 1 siteChina
- Study dates
- 1 Aug 2026to 1 Aug 2026
- Phase
- Observational
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 to 85 years
- Women only
- No healthy volunteers
- Adult, Older adult
Study population: Retrospective study of female patients with node-positive breast cancer receiving axillary lymph node dissection, comparing robotic-assisted versus endoscopic-assisted surgical approaches.
Who may be able to join
- Female patients aged 18-85 years;
- Pathologically confirmed node-positive breast cancer;
- Underwent robotic-assisted or endoscopic-assisted axillary lymph node dissection;
- Complete clinical and perioperative data available.
Who cannot join
- History of prior axillary surgery or radiotherapy;
- Distant metastatic disease;
- Severe cardiopulmonary, hepatic or renal dysfunction unsuitable for surgery;
- Incomplete clinical data. -
Trial locations and contacts
1 site in 1 country.
China1 site
Guangzhou Women and Children's Medical Center, Guangzhou Medical University
Guangzhou, Guangdong, 510623
About this study
Official title: Efficacy and Safety of Robotic-Assisted Remote Surgery for Breast Tumors
This is a multicenter retrospective clinical study. The research aims to explore the safety and efficacy of robotic single-port thoracoscopic minimally invasive surgery for breast cancer patients. Patients receiving robotic single-port thoracoscopic surgery for breast tumors will be enrolled. We will collect perioperative indicators, postoperative complications and follow-up data to compare clinical outcomes, so as to provide evidence for the clinical application of remote robotic single-port thoracoscopic surgical technology in breast oncology.
Read the detailed description
This is a multicenter retrospective observational clinical study. Subjects are patients diagnosed with breast cancer who underwent robotic single-port thoracoscopic surgery. The study collects clinical data including operation time, intraoperative blood loss, drainage volume, hospital stay, postoperative complications, short-term recovery status and follow-up outcomes. The primary objective is to evaluate the safety and efficacy of robotic single-port thoracoscopic minimally invasive surgery in breast tumor surgery. Secondary objectives include analyzing perioperative characteristics and postoperative recovery indexes. Patients will be divided according to surgical methods for comparative analysis. All data will be collected retrospectively from electronic medical records without additional experimental interventions. The study has obtained ethical approval.
- Conditions
- Breast Neoplasms
- Being tested
- Robotic-assisted axillary lymph node dissection
- Keywords
- Breast cancer, robotic surgery, single-port thoracoscopic surgery, minimally invasive operation, axillary lymph node dissection, retrospective clinical study
- Medical subject headings
- Breast Neoplasms
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Robotic-assisted axillary lymph node dissectionProcedure or surgery
Robotic-assisted axillary lymph node dissection for breast cancer patients with positive lymph nodes
Robotic-assisted axillary lymph node dissectionProcedure or surgery
Robotic-assisted axillary lymph node dissection is performed for patients with node-positive breast cancer
| Study group | Role | What they receive |
|---|---|---|
| Endoscopic-assisted axillary lymph node dissection group | Patients receiving endoscopic-assisted axillary lymph node dissection Receives: Procedure: Robotic-assisted axillary lymph node dissection |
What is being measured
The primary outcome is the main question the study is designed to answer.
Incidence of postoperative axillary complications
Incidence of postoperative axillary complications
Measured: 30 days after surgery
Incidence of postoperative axillary complications
The incidence of postoperative axillary complications including seroma, hematoma, wound infection and upper limb lymphedema after axillary lymph node dissection.
Measured: 30 days after surgery
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted30 Sep 2026
- Study start1 Aug 2026
- Primary completion1 Aug 2026
- Study completion1 Aug 2026
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Breast NeoplasmsStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Cohort
- Time perspective
- Retrospective
- Enrolment
- 25 participants (actual)
Sponsor and investigators
- Lead sponsor
- Guangzhou Women and Children's Medical Center
- Sponsor type
- University, hospital or other
- Responsible party
- Principal investigator, haiyanli, Guangzhou Women and Children's Medical Center
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07850323
- Sponsor's protocol ID
- SR-BC-202601
- Status last verified
- Sep 2026
- First submitted
- 3 Aug 2026
- Last updated
- 30 Sep 2026
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
Study at a glance
From the registry record, last updated by the sponsor on 30 Sep 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Efficacy and Safety of Robotic-Assisted Remote Surgery for Breast Tumors
- ClinicalTrials.gov ID
- NCT07850323
- Acronym / sponsor ID
- SR-BC-202601
- Conditions
- Breast Neoplasms
- Keywords
- Breast cancer, robotic surgery, single-port thoracoscopic surgery, minimally invasive operation, axillary lymph node dissection, retrospective clinical study
- Study type
- Observational
- Recruitment status
- Completed
- Enrolment
- 25 participants (actual)
- Lead sponsor
- Guangzhou Women and Children's Medical CenterUniversity, hospital or other
- Study start
- 1 Aug 2026 (actual)
- Primary completion
- 1 Aug 2026 (actual)
- Study completion
- 1 Aug 2026 (actual)
- First posted
- 30 Sep 2026 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
This is a multicenter retrospective clinical study. The research aims to explore the safety and efficacy of robotic single-port thoracoscopic minimally invasive surgery for breast cancer patients. Patients receiving robotic single-port thoracoscopic surgery for breast tumors will be enrolled. We will collect perioperative indicators, postoperative complications and follow-up data to compare clinical outcomes, so as to provide evidence for the clinical application of remote robotic single-port thoracoscopic surgical technology in breast oncology.
Detailed description
This is a multicenter retrospective observational clinical study. Subjects are patients diagnosed with breast cancer who underwent robotic single-port thoracoscopic surgery. The study collects clinical data including operation time, intraoperative blood loss, drainage volume, hospital stay, postoperative complications, short-term recovery status and follow-up outcomes. The primary objective is to evaluate the safety and efficacy of robotic single-port thoracoscopic minimally invasive surgery in breast tumor surgery. Secondary objectives include analyzing perioperative characteristics and postoperative recovery indexes. Patients will be divided according to surgical methods for comparative analysis. All data will be collected retrospectively from electronic medical records without additional experimental interventions. The study has obtained ethical approval.
Study design
- Observational model
- Cohort
- Time perspective
- Retrospective
- Number of arms
- 1
| Arm | Type | Receives |
|---|---|---|
| Endoscopic-assisted axillary lymph node dissection group | – | Procedure: Robotic-assisted axillary lymph node dissectionPatients receiving endoscopic-assisted axillary lymph node dissection |
Who may qualify
- Ages
- 18 to 85 years
- Sex
- Female only
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
- Study population
- Retrospective study of female patients with node-positive breast cancer receiving axillary lymph node dissection, comparing robotic-assisted versus endoscopic-assisted surgical approaches.
Key inclusion criteria (4 listed)
- Female patients aged 18-85 years;
- Pathologically confirmed node-positive breast cancer;
- Underwent robotic-assisted or endoscopic-assisted axillary lymph node dissection;
- Complete clinical and perioperative data available.
Key exclusion criteria (4 listed)
- History of prior axillary surgery or radiotherapy;
- Distant metastatic disease;
- Severe cardiopulmonary, hepatic or renal dysfunction unsuitable for surgery;
- Incomplete clinical data. -
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Robotic-assisted axillary lymph node dissectionRobotic-assisted axillary lymph node dissection for breast cancer patients with positive lymph nodes | Procedure or surgery | Endoscopic-assisted axillary lymph node dissection group |
| Robotic-assisted axillary lymph node dissectionRobotic-assisted axillary lymph node dissection is performed for patients with node-positive breast cancer | Procedure or surgery | Endoscopic-assisted axillary lymph node dissection group |
Primary outcome
Incidence of postoperative axillary complications
Time frame: 30 days after surgery
Incidence of postoperative axillary complications
Incidence of postoperative axillary complications
Time frame: 30 days after surgery
The incidence of postoperative axillary complications including seroma, hematoma, wound infection and upper limb lymphedema after axillary lymph node dissection.
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 30 Sep 2026.
Related trials for Breast Neoplasms
Active, not recruiting
Streamlined Geriatric and Oncological Evaluation Based On IC Technology
Breast Cancer, Comorbidities and Coexisting Conditions
RecruitingPhase 2
Gene Signatures to Guide HR+MBC Therapy in a Diverse Cohort
Invasive Mammary Carcinoma, Metastatic Breast Cancer
Not yet recruitingObservational study
Comparison of Reliability, Time Cost, and Participant Comfort of Lymphedema Assessments in Upper Extremity
Lymphedema, Upper Extremity Lymphedema
RecruitingPhase 3
A Study of Camrelizumab Plus Chemotherapy in Combination With or Without Famitinib as Neoadjuvant Therapy in Participants With Triple Negative Breast Cancer (BCTOP-T-N01)
TNBC - Triple-Negative Breast Cancer
RecruitingPhase 3
Testing Whether Hormone Therapy With Ribociclib is as Effective as Chemotherapy Followed by Hormone Therapy With Ribociclib for the Treatment of High Anatomic Stage Breast Cancer With Low Recurrence Risk, The RxFINE-Low Trial
Anatomic Stage II Breast Cancer AJCC v8, Anatomic Stage IIIA Breast Cancer AJCC v8
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
The record lists no contact. Use the official record to reach the sponsor.
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Breast Neoplasms, run by Guangzhou Women and Children's Medical Center at 1 site in China.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 4 inclusion and 4 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 30 Sep 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in China. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Incidence of postoperative axillary complications (time frame: 30 days after surgery). The study lists 2 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 30 Sep 2026.